Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?
about
The non-genomic crosstalk between PPAR-gamma ligands and ERK1/2 in cancer cell linesThe nuances of atherogenic dyslipidemia in diabetes: focus on triglycerides and current management strategies.AVE8134, a novel potent PPARα agonist, improves lipid profile and glucose metabolism in dyslipidemic mice and type 2 diabetic rats.Lack of association between adiponectin levels and atherosclerosis in mice.Randomized comparison of the effects of rosiglitazone vs. placebo on peak integrated cardiovascular performance, cardiac structure, and functionEvolution of peroxisome proliferator-activated receptor agonists.Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes.Identification of a novel selective agonist of PPARγ with no promotion of adipogenesis and less inhibition of osteoblastogenesis.Berberine nanosuspension enhances hypoglycemic efficacy on streptozotocin induced diabetic C57BL/6 mice.Saroglitazar, a novel PPARα/γ agonist with predominant PPARα activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models.Peroxisome proliferator-activated receptor-γ agonists repress epithelial sodium channel expression in the kidney.Peroxisome Proliferator-Activated Receptors and the Heart: Lessons from the Past and Future Directions.Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects.Rosiglitazone attenuates insulin-like growth factor 1 receptor survival signaling in PC-3 cellsThiazolidinediones and risk for atherosclerosis: pleiotropic effects of PPar gamma agonism.Thiazolidinedione-induced fluid retention: recent insights into the molecular mechanisms.Measuring biomarkers to assess the therapeutic effects of PPAR agonists?Pharmacogenetics of the PPAR genes and cardiovascular disease.Antioxidant supplemention in the treatment of skeletal muscle insulin resistance: potential mechanisms and clinical relevance.Toxicological evaluation of subchronic use of pioglitazone in mice.Increased susceptibility of db/db mice to rosiglitazone-induced plasma volume expansion: role of dysregulation of renal water transporters.PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury.Renal epidermal growth factor receptor: its role in sodium and water homeostasis in diabetic nephropathy.Interruptin B induces brown adipocyte differentiation and glucose consumption in adipose-derived stem cells.Analysis of PPAR-α/γ Activity by Combining 2-D QSAR and Molecular Simulation.Activation of peroxisome proliferator-activated receptor-γ downregulates soluble epoxide hydrolase in cardiomyocytes.Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure.Differential effects of pioglitazone on metabolic parameters in newly diagnosed, drug-naïve Japanese patients with type 2 diabetes with or without metabolic syndrome.The effect of rosiglitazone on integrated cardiovascular performance, cardiac structure, function and myocardial triglyceride: trial design and rationale.Hereditary Nephrogenic Diabetes Insipidus: Pathophysiology and Possible Treatment. An Update.
P2860
Q28238709-228703B0-6260-4326-B79E-D170183664DFQ30357715-C8C86327-8E6A-4F5B-8F2C-881649D3460CQ33567011-C6ADE7DF-9094-40E2-82E9-7E1F39CE86E1Q33958420-19BFB9B8-5B44-432C-BC7C-6BAB97470861Q34123775-E040CC12-A7D8-4CDC-8DD1-0F58E4051917Q34630829-5191C195-960C-4523-AEE9-D239904D0BD9Q34695851-948E72F7-A3F5-4767-8CAD-FEA59B901766Q35237706-E2D9059A-2CD0-4352-8BB2-43BC160CDC94Q35239952-D5DC499C-E799-4668-A928-C4CAEB326D2BQ35822331-B378DD09-90E0-4F7B-AD0E-17609C9551EFQ35964478-9213E01B-5ADD-445C-B1E1-6E1F871BA17CQ36261125-C82A9D04-4A4D-41B1-9EA9-E4BC6EC1059CQ36569766-C8095501-9F65-4035-9643-6FBBF234C5C6Q36608691-4BEAAF64-B280-4EE8-BA1D-64C69BABFC44Q36632030-829002E5-BDB7-49BF-B84B-F2CCD2CA661AQ36734040-2641309E-E959-4FCA-8148-2EEC07810EC9Q37012012-1EC65BB2-7921-44C0-8CB0-8095694A2F0BQ37012017-DCAEF3FF-9A6E-412B-A58B-533B297099F9Q37112535-C6B3CB8E-84D3-4FFB-9E58-CB42BAABE12CQ37231096-2E0D0B53-C9A1-4ADE-874C-47A0AEC3468CQ37342122-1A5674AE-B635-4A92-8A55-95064D87FB47Q37362740-9853BAE2-677B-4FF4-9156-F7676624DF36Q37820693-89D72059-7C66-44C4-8403-656ABBD36DEEQ38651575-172E2182-7A83-4B9C-AEEB-44BAF0D54059Q39535351-F80F4097-E02F-4B9F-9541-CE8A5C820A13Q39598383-142C9DCB-D225-4AAB-B38B-762A6B969E3FQ41267217-08D485F9-FF62-4FB9-B438-76F1DA1D6A0BQ42936496-5F932FFD-5ED4-4056-8D08-39FB1A180A9CQ46155234-2549922C-51EB-4FF1-B548-19C4D351F6D3Q47802729-439AD480-5E05-4E6A-BB92-07015144169E
P2860
Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?
@ast
Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?
@en
type
label
Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?
@ast
Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?
@en
prefLabel
Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?
@ast
Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?
@en
P2093
P2860
P356
P1476
Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?
@en
P2093
Chetan Patel
Darren K McGuire
Kathleen L Wyne
P2860
P356
10.3132/DVDR.2005.010
P407
P577
2005-05-01T00:00:00Z